←Front page
HealthNational
multiQure begins manufacturing phase of MQ─201 gene therapy for Huntington's disease; selects Andelyn Biosciences as manufacturing partner
multiQure S.A., a biotechnology company developing an RNAi gene therapy for Huntington's disease, is moving into the manufacturing phase of its MQ─201 therapy.
Balanced coverage
0% L100% C0% R
1 outlet covering this story
Bias Comparison
No AI summary generated for this bucket yet.
1 Article
- multiQure begins manufacturing phase of MQ─201 gene therapy for Huntington's disease; selects Andelyn Biosciences as manufacturing partnerPharma BizCenter
Discussion (0)
Sign in to share your opinion.
- No comments yet — be the first to weigh in.
